Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT07620457
Starting soon Observational

Spectral Precise Image Study for Coronary Artery

NCT07620457 · tracked via the Priya Life Science China tracker
Sponsor
Philips Clinical & Medical Affairs Global
Phase
Observational
Started
2026-06-01
Last updated
2026-06-02

Condition(s) studied

Cardiac

Investigational drug(s) / intervention(s)

Non-Interventional StudyNon-Interventional Study

Non-Interventional Study: This is an observational study

Non-Interventional Study: This is an observational study

Study summary

This is a single-center, comparative, observational, retrospective data study. Datasets from patients who underwent spectral coronary CT angiography (CCTA) for suspected coronary artery disease (CAD) or other diagnosis needs as part of their routine clinical evaluation will be included.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: 1. Datasets from Patients who underwent spectral coronary CT angiography (CCTA). 2. Datasets from study participants with age ≥ 18 years old. 3. Scan parameters that meet the criteria defined in the 5.4.3. Exclusion Criteria: 1. The clinical data information is considered incomplete after evaluation by the investigator. 2. The investigator determined that poor image quality (e.g. obvious artifacts, missing critical scan layers) would not satisfy post-processing analysis. 3. Data of patients deemed inappropriate for inclusion after evaluation by the investigator.

Primary outcome measure(s)

  • Subjective Image quality using 5 Liket-scale (1-5) — From date of image reconstruction until the date of image reading completion, anticipated 3Months.
    The subjective image quality will be assessed by 2 radiologists using Liket-scale on a range from 1(poor) to 5(Excellent).

Trial sites (1)

FacilityCityRegionStatus
Zhengzhou Universtidy 1st Affiliated Hospital Zhengzhou Henan

More Philips Clinical & Medical Affairs Global trials in China

Spectral Precise Image Study for Brain Tumors Recruiting
Clinical Study of Spectral CT Starting soon
Clinical Study of Spectral CT Verida Starting soon
Spectral Precise Image-Colon Cancer Starting soon

Other trials for the same condition

AI-Generated Video Feedback to Improve Technical Skills in Coronary Artery Bypass Grafting Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07620457 on ClinicalTrials.gov ↗ ← All trials in China